Edgewise Therapeutics (EWTX) Expected to Announce Quarterly Earnings on Thursday

Edgewise Therapeutics (NASDAQ:EWTX) is anticipated to announce its Q1 2025 earnings results before the market opens on Thursday, May 8th. Analysts expect the company to announce earnings of ($0.45) per share for the quarter.

Edgewise Therapeutics (NASDAQ:EWTX) last released its quarterly earnings results on Monday, March 3rd. The company reported ($0.42) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.03). On average, analysts expect Edgewise Therapeutics to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Edgewise Therapeutics Price Performance

Edgewise Therapeutics stock opened at $16.54 on Tuesday. The firm has a market capitalization of $1.73 billion, a P/E ratio of -11.03 and a beta of 0.36. The company’s 50-day moving average is $19.14 and its 200 day moving average is $26.06. Edgewise Therapeutics has a 1-year low of $10.60 and a 1-year high of $38.12.

Insider Activity at Edgewise Therapeutics

In other news, insider Alan J. Russell sold 1,200 shares of the stock in a transaction on Thursday, February 6th. The stock was sold at an average price of $30.13, for a total transaction of $36,156.00. Following the completion of the sale, the insider now owns 14,863 shares in the company, valued at approximately $447,822.19. This represents a 7.47 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Kevin Koch sold 8,636 shares of the business’s stock in a transaction on Wednesday, February 5th. The stock was sold at an average price of $30.03, for a total value of $259,339.08. Following the transaction, the chief executive officer now owns 14,478 shares in the company, valued at approximately $434,774.34. This trade represents a 37.36 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 24.11% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of equities analysts recently issued reports on EWTX shares. Piper Sandler restated an “overweight” rating and set a $51.00 price objective on shares of Edgewise Therapeutics in a report on Wednesday, April 2nd. Guggenheim started coverage on shares of Edgewise Therapeutics in a research note on Wednesday, April 30th. They issued a “buy” rating and a $41.00 price target on the stock. Wedbush reissued an “outperform” rating and issued a $43.00 price objective on shares of Edgewise Therapeutics in a research report on Monday, April 21st. Stifel Nicolaus began coverage on shares of Edgewise Therapeutics in a research report on Wednesday, January 22nd. They set a “hold” rating and a $30.00 target price on the stock. Finally, Scotiabank downgraded shares of Edgewise Therapeutics from a “sector outperform” rating to a “sector perform” rating and decreased their price target for the company from $50.00 to $14.00 in a research note on Wednesday, April 2nd. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $40.22.

Edgewise Therapeutics Company Profile

Edgewise Therapeutics, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.